Western drugmakers suffered a major blow after the Indian Supreme Court rejected Novartis' petition for patent protection for its cancer treatment Glivec. The landmark ruling sets a reference point for other intellectual-property disputes in the country and is likely to affect many other drugmakers and their brand-name treatments, analysts say.

Full Story:

Related Summaries